NYSE
266.03USD
-3.41 (-1.27%)
We have scored 22 news catalysts on IQVIA Holdings Inc. (IQV) over the past 12 months. The biggest single-day move next to one of them came Feb 28, 2026, when IQV closed +4.8%: “IQVIA Holdings: Still Exceeding Expectations As A Stealth Compounder”. Coverage across the window leans positive (average ticker sentiment +0.39). Most of the impact sits in sector healthcare and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
44B
P/E
—
EPS
—
Beta
1.19
52W range
154.5-273.88
Day range
265.80–269.45
Open
269.45
Prev close
269.44
Volume
624.6K
Avg volume
1.5M
Dividend
0.00
IPO
2013-05-09
Analysts publish price targets on IQV, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
9 analyst price targets from $200 to $287
as of 2026-09-05
The market is 12% above the median target — more optimistic than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about IQVIA Holdings Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for IQV: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
The reconstruction
The price sits 12% above the median published target and at the 78th percentile by count, meaning the market is already paying for a bullish outcome that most analysts have not yet formally endorsed.
What the disagreement turns on
Whether the Technology and Analytics segment can sustain enough volume growth to push the overall company toward a 10.3% revenue CAGR and close the cash flow gap; this is testable using wired segment revenue history, though direct cash flow measurement is not.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
